New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:40 EDTEXELSummer Street's chief scientific officer holds analyst/industry conference call
Chief Science Officer Classen discusses Exelixis' Cabozantinib for treatment of mestastatic prostate cancer on an Analyst/Industry conference call to be held on March 20 at 10 am.
News For EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
08:07 EDTEXELExelixis announces positive overall survival results from Meteor trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use